Inhibrx Announces Positive Interim Results From HexAgon Trial

Why It Matters

The results suggest that OX40 agonism can substantially boost immunotherapy efficacy in a hard‑to‑treat cancer, potentially reshaping combination strategies and attracting new investment.

Key Takeaways

• Combination arm 44% response vs 21% control
• Three complete responses observed only with INBRX‑106 combo
• CD8+ and CD4+ T cells expanded up to 15‑fold
• Safety profile manageable; no treatment‑related deaths
• Phase III slated Q3 2026; PFS data Q4 2026

Pulse Analysis

The treatment landscape for metastatic or unresectable recurrent head and neck squamous cell carcinoma (HNSCC) has been dominated by checkpoint inhibitors such as pembrolizumab, yet durable responses remain limited. Biopharma firms are exploring costimulatory pathways to amplify T‑cell activity, and the OX40 receptor has emerged as a promising target. INBRX‑106, a hexavalent OX40 agonist, is designed to synergize with PD‑L1 blockade, aiming to overcome immune resistance that hampers current standards of care.

The interim data from Inhibrx’s Phase II HexAgon study provide the first clinical signal that this strategy can translate into higher response rates. Among 25 evaluable patients receiving INBRX‑106 plus pembrolizumab, 44 % achieved an objective response, compared with 21 % on pembrolizumab alone, and three patients experienced complete tumor regression. Pharmacodynamic analyses revealed up to a 15‑fold surge in circulating CD8⁺ and CD4⁺ T‑cells, indicating robust immune activation. Adverse events were predominantly low‑grade, with rash, diarrhea, fatigue and infusion reactions, and no treatment‑related deaths were reported.

These findings position OX40 agonism as a potential game‑changer for immuno‑oncology, offering a pathway to lift the efficacy ceiling of existing checkpoint therapies. Investors are likely to view the upcoming Phase III readout, slated for the third quarter of 2026, as a pivotal milestone that could unlock larger combination programs, including novel antibody‑drug conjugates or cellular therapies. If the efficacy signal holds, INBRX‑106 could attract partnership interest from major pharma, accelerate funding rounds, and reshape treatment algorithms for PD‑L1‑positive HNSCC.